VCs in €40m series-D for Themis

Also participating were new investors MDS and Adjuvant Capital, and existing investors Global Health Investment Fund (GHIF), AWS Gründerfonds, Omnes Capital, Ventech and Wellington Partners Life Sciences.

The fresh capital will be used to accelerate the company's phase-III clinical trial programme for its chikungunya vaccine and to support further expansion into oncology indications using its proprietary measles vaccine vector platform.

Hadean managing partner Walter Stockinger will join Themis's supervisory board.

Previous funding
Ventech led a €5m series-A funding round for Themis in May 2011. The investor returned in November 2016 to take part in a €10m series-B along with AWS Gründerfonds, Omnes Capital and Wellington Partners.

GHIF led a €10m series-C funding round for the company in 2018, with participation from AWS, Omnes, Ventech and Wellington Partners Life Sciences.

Company
Vienna-based Themis was founded in 2009 and is a specialist developer of vaccines for emerging infectious diseases. The company employs 28 people, according to LinkedIn.

People
Hadean Ventures – Walter Stockinger (managing partner).
Themis – Erich Tauber (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• healthcare
• United Kingdom
• Venture